Hexvix (Hexaminolevulinate)

Hexvix is indicated for visual enhancement of bladder lesions during cystoscopic examination.

• Detection of non‑muscle‑invasive bladder cancer (NMIBC) during standard white‑light cystoscopy.
• Identification of carcinoma in situ (CIS) of the bladder.
• Guidance of transurethral resection of bladder tumor (TURBT) by highlighting suspicious areas.
• Assessment of treatment response or recurrence in patients under surveillance.
• Differentiation between inflammatory changes and true malignant lesions.
• Facilitation of targeted biopsies to improve diagnostic yield.

• Hexvix contains hexaminolevulinate, a prodrug that is preferentially taken up by malignant urothelial cells. Inside these cells, enzymatic conversion produces protoporphyrin IX, a fluorescent porphyrin. When the bladder is illuminated with blue light (approximately 375–440 nm), protoporphyrin IX emits a red‑violet fluorescence, allowing clinicians to distinguish cancerous tissue from normal mucosa during cystoscopy. The selective accumulation results from higher metabolic activity and altered heme biosynthesis pathways in tumor cells.

Adverse reactions to Hexvix are generally related to the intravesical administration and the photosensitizing properties of the agent.

Common

• Mild bladder irritation or dysuria, usually resolving within hours.
• Transient hematuria that clears without intervention.
• Increased urinary urgency or frequency during the observation period.
• Mild flank discomfort or pelvic pressure after instillation.

Serious

• Severe allergic reaction, including anaphylaxis or angioedema, requiring immediate medical attention.
• Persistent urinary retention that may necessitate catheter placement.
• Phototoxic skin reaction if the patient is exposed to intense light sources before the drug is cleared.

Before using Hexvix, clinicians should evaluate several safety considerations to minimize risks associated with the procedure and the photosensitizer.

• Confirm absence of active urinary tract infection prior to instillation.
• Ensure the patient has not received porphyrin‑related drugs (e.g., certain antibiotics, antimalarials) within the past two weeks.
• Verify that the bladder is adequately drained and that no obstructive lesions are present.
• Advise patients to avoid direct sunlight and strong indoor lighting for at least 24 hours after the procedure.
• Monitor for signs of allergic reaction during and after administration.
• Use caution in patients with known hypersensitivity to aminolevulinic acid derivatives.
• Pregnancy status is unknown; avoid use unless benefits outweigh potential risks.

Hexvix may interact with other agents that affect porphyrin metabolism or cause photosensitivity.

Avoid

• Concurrent use of other photosensitizing drugs (e.g., tetracyclines, sulfonamides, amiodarone) that could amplify fluorescence or skin reactions.
• Administration of porphyrin‑inducing agents such as phenobarbital or griseofulvin within two weeks before the procedure.

Use with caution

• Systemic chemotherapy or immunotherapy that may alter bladder mucosa integrity; monitor for increased irritation.
• Anticoagulant therapy, as minor hematuria may be more pronounced.
• Use of intravesical agents (e.g., BCG) shortly before or after Hexvix; schedule appropriately to avoid overlapping effects.